300 related articles for article (PubMed ID: 8205303)
1. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin.
Tison P; Ulicna L; Jakubovska Z; Oravcova J; Fetkovska N
Blood Press Suppl; 1994; 1():57-60. PubMed ID: 8205303
[TBL] [Abstract][Full Text] [Related]
2. Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension.
Tison P; Ulicna L; Jakubovska Z; Oravcova J; Fetkovska N
Am J Hypertens; 1994 Jul; 7(7 Pt 2):46S-49S. PubMed ID: 7946179
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypertension with calcium antagonists and aspirin. Effects on 24-h platelet activity.
Fetkovska N; Jakubovska Z; Oravcova J; Tison P; Ulicna L; Trnovec T
Am J Hypertens; 1993 Mar; 6(3 Pt 2):98S-101S. PubMed ID: 8466742
[TBL] [Abstract][Full Text] [Related]
4. [Circadian antihypertensive action and tolerability of a sustained-release form of isradipine in an intra-individual comparison with nitrendipine].
Lohmann FW; Welzel D; Burger KJ
Arzneimittelforschung; 1993 May; 43(5):522-5. PubMed ID: 8328996
[TBL] [Abstract][Full Text] [Related]
5. Serotonin and platelet activation during treatment with isradipine.
Fetkovska N; Sebekova K; Fedelesova V; Dzurik R
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S31-3. PubMed ID: 1720482
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension.
Fitscha P; Meisner W; Hitzenberger G
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S12-4. PubMed ID: 1720478
[TBL] [Abstract][Full Text] [Related]
7. Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension.
Ding YA; Han CL; Chou TC; Lai WY; Shiao MF
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S32-7. PubMed ID: 1376832
[TBL] [Abstract][Full Text] [Related]
8. [Circadian antihypertensive effect of sustained-release isradipine in patients with essential hypertension in comparison to placebo].
Burger KJ; Anlauf M
Arzneimittelforschung; 1993 Sep; 43(9):958-62. PubMed ID: 8240458
[TBL] [Abstract][Full Text] [Related]
9. [Multicenter study of isradipine in the treatment of hypertension].
Widimský J; Dzúrik R; Fet'kovská N; Balazovjech I; Kvasnicka J; Lupínek Z; Mayer O; Pidrman V
Vnitr Lek; 1992 Apr; 38(4):317-25. PubMed ID: 1352927
[TBL] [Abstract][Full Text] [Related]
10. The use of calcium antagonists to treat intra-operative hypertension--evaluation of efficacy and safety of a new dihydropyridine derivative, intravenous isradipine, during abdominal surgery.
Edouard A; Dartayet B; Ruegg C; Samii K
Eur J Anaesthesiol; 1991 Sep; 8(5):351-8. PubMed ID: 1834462
[TBL] [Abstract][Full Text] [Related]
11. [Antihypertensive effect and adverse effects of isradipine in patients with sever hypertension. Results of an open multicenter study].
Burger KJ; Dehner R
Arzneimittelforschung; 1996 Jun; 46(6):600-5. PubMed ID: 8767350
[TBL] [Abstract][Full Text] [Related]
12. The antihypertensive action of isradipine in mild essential hypertension.
Viskoper JR; Laszt A; Farragi D
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S9-11. PubMed ID: 1720488
[TBL] [Abstract][Full Text] [Related]
13. Parallel comparative trial of amlodipine and nitrendipine monotherapy in patients with essential hypertension.
Wang X; Gong L; Guo J; Wang X; Liu Y; Ye X; Zhang G; Yang P
J Hypertens Suppl; 1998 Sep; 16(4):S43-7. PubMed ID: 9817192
[TBL] [Abstract][Full Text] [Related]
14. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
Jern S; Hansson L; Scherstén B; Kullman S; Sörensen S; Dahlöf B; Eggertsen R; Sivertsson R
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S7-8. PubMed ID: 1720487
[TBL] [Abstract][Full Text] [Related]
15. Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. Swiss Hypertension Society.
Lüscher TF; Waeber B
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S1-3. PubMed ID: 1720476
[TBL] [Abstract][Full Text] [Related]
16. Reduced platelet thromboxane formation after long-term administration of a dihydropyridine calcium channel blocker: a prospective, double-blind, placebo-controlled study with nitrendipine in borderline hypertensive patients with IDDM-type diabetes mellitus.
Tschoepe D; Homberg M; Roesen P; Gries FA
Diabetes Res; 1992 Mar; 19(3):125-31. PubMed ID: 1286547
[TBL] [Abstract][Full Text] [Related]
17. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers.
Winther K; Gleerup G; Hedner T
J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S41-4. PubMed ID: 1725542
[TBL] [Abstract][Full Text] [Related]
18. Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension.
Dahlöf B; Andrén L; Eggertsen R; Jern S; Svensson A; Sievert A; Aurell M; Hansson L
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S102-4. PubMed ID: 2455104
[TBL] [Abstract][Full Text] [Related]
19. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus.
Klauser R; Speiser P; Gisinger C; Schernthaner G; Prager R
J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S93-6. PubMed ID: 1695314
[TBL] [Abstract][Full Text] [Related]
20. Effects of benidipine hydrochloride on 24-hour blood pressure and blood pressure response to mental stress in elderly patients with essential hypertension.
Muneta S; Kohara K; Hiwada K
Int J Clin Pharmacol Ther; 1999 Mar; 37(3):141-7. PubMed ID: 10190762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
